Parallax Volatility Advisers’s Alexion Pharmaceuticals ALXN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-10,300
Closed -$1.18M 3357
2020
Q3
$1.18M Buy
+10,300
New +$1.11M ﹤0.01% 1927
2020
Q2
Sell
-800
Closed -$72K 2954
2020
Q1
$72K Sell
800
-2,800
-78% -$275K ﹤0.01% 2201
2019
Q4
$390K Sell
3,600
-26,800
-88% -$2.87M ﹤0.01% 1821
2019
Q3
$2.98M Buy
30,400
+27,400
+913% +$3.09M ﹤0.01% 994
2019
Q2
$393K Sell
3,000
-60,900
-95% -$7.85M ﹤0.01% 1573
2019
Q1
$8.64M Sell
63,900
-52,900
-45% -$6.58M 0.01% 522
2018
Q4
$11.4M Buy
116,800
+1,900
+2% +$225K 0.02% 481
2018
Q3
$16M Buy
+114,900
New +$14.4M 0.02% 353
2017
Q3
Sell
-40,000
Closed -$4.87M 3615
2017
Q2
$4.87M Hold
40,000
0.01% 576
2017
Q1
$4.85M Buy
+40,000
New +$5.16M 0.01% 594
2016
Q3
Sell
-50,000
Closed -$5.84M 4215
2016
Q2
$5.84M Hold
50,000
0.01% 583
2016
Q1
$6.96M Sell
50,000
-500
-1% -$73.4K 0.02% 468
2015
Q4
$9.63M Buy
50,500
+500
+1% +$87.3K 0.02% 473
2015
Q3
$7.82M Buy
+50,000
New +$9.12M 0.02% 533
2014
Q2
Sell
-10,000
Closed -$1.52M 4377
2014
Q1
$1.52M Buy
+10,000
New +$1.59M 0.01% 649

Other funds holding ALXN

Parallax Volatility Advisers's ALXN Position: Q4 2020 in Review

Parallax Volatility Advisers sold out of Alexion Pharmaceuticals (ALXN) in Q4 2020, closing a stake of 1,181 shares — an estimated $135K sold.

Parallax Volatility Advisers first reported a position in ALXN in Q1 2014 and held it in 12 quarters. The position peaked at $6.46M in Q2 2020. 825 funds tracked by Wall St. Rank hold ALXN as of Q4 2020.

  • Parallax Volatility Advisers reported no remaining Alexion Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Parallax Volatility Advisers sold 1,181 Alexion Pharmaceuticals shares in Q4 2020, an estimated $135K.
  • Parallax Volatility Advisers first reported a position in Alexion Pharmaceuticals in Q1 2014 and held it in 12 quarters.
  • Parallax Volatility Advisers's Alexion Pharmaceuticals position peaked at $6.46M in Q2 2020.
  • 825 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2020.

Based on Parallax Volatility Advisers's 13F filing for Q4 2020, filed 16 Feb 2021.